Pharminent

FDA approves Click’s digital therapeutic Motivista for schizophrenia

Click Therapeutics said it received the first-ever FDA approval of a treatment for the negative symptoms of schizophrenia, a digital therapeutic called Motivista.

AbbVie and Genmab’s Epkinly succeeds in frontline DLBCL trial

AbbVie and Genmab reported positive results from the EPCORE trial of the bispecific antibody Epkinly in newly diagnosed diffuse large B-cell lymphoma.

ArriVent shares fall by half on furmonertinib lung cancer data

More than half of ArriVent’s market value was wiped out after the company reported results for furmonertinib in EGFR-mutated lung cancer.

Amplio reports Phase 1b data for NovoBioJect in rheumatoid arthritis

Amplio Pharma reported Phase 1b results for NovoBioJect, a combination of low-dose methotrexate and novobiocin being developed as a potential first-line treatment for rheumatoid arthritis; in the 12-patient study, a single dose produced a 38% increase in intracellular long-chain methotrexate polyglutamates (MTX-PG4 and MTX-PG5) compared with methotrexate alone.

Gilead signs five-year DevOps agreement extension with Cognizant

Gilead Sciences signed a five-year agreement extension with Cognizant to advance its DevOps environment and support deployment of agentic AI tools across designated technology initiatives.

Caribou Biosciences shutting down after failing to raise funds

Caribou Biosciences, co-founded by Jennifer Doudna, is shutting down after failing to raise the money needed to fund a late-stage clinical trial of its off-the-shelf CAR-T therapy for lymphoma.

Adecto and Aviceda wind down operations

Biotechs Adecto and Aviceda are winding down their operations, while Caribou is in peril.

AstraZeneca opens new R&D site in Cambridge, Massachusetts

AstraZeneca opened a new R&D site in Kendall Square in Cambridge, Massachusetts, the centerpiece of a $1 billion investment in the state.

KymaThera raises $80M Series B for breast cancer drug

KymaThera raised $80 million in a Series B financing and plans to dose the first patients in a Phase I trial of K-1728, an oral selective PI3K-alpha inhibitor, in breast cancer in the fourth quarter of 2026.

Rocket secures $150M credit facility from Hercules Capital

Rocket Pharmaceuticals entered into a credit facility agreement of up to $150 million with Hercules Capital to support ongoing development of its cardiovascular portfolio.